Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Thyroid Assays Covered by Blue Shield of California

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Blue Shield of California has agreed to cover Interpace's combination molecular thyroid tests, ThyGenX and ThyraMir.

Blue Shield of California, which serves more than 4 million health plan members and 65,000 physicians in the state, published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.

This is the eighth Blue Cross Blue Shield plan to grant positive coverage for Interpace's tests this year, bringing the total number of covered lives to 285 million.

ThyGenX-ThyraMir combination testing can help determine the presence and absence of cancer in thyroid nodules. Testing includes the rule-in properties of next-generation sequencing of a patient's DNA and RNA and the rule-out capabilities of a microRNA classifier, respectively. Based on current performance, about 90 percent of ThyGenX cases are reflexed to ThyraMir for additional assessment, Interpace said.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.